Soleno Therapeutics (SLNO) Financials

$75.05 -0.53 (-0.70%)

Closing price 05/20/2025 04:00 PM Eastern

Extended Trading

$75.00 -0.05 (-0.07%)

As of 08:57 AM Eastern

Annual Income Statements for Soleno Therapeutics

This table shows Soleno Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Net Income / (Loss) Attributable to Common Shareholders	-176	-39	-24	-31	-25	-31	-13	-15	-16	-16
Consolidated Net Income / (Loss)	-176	-39	-24	-31	-25	-31	-13	-15	-12	-16
Net Income / (Loss) Continuing Operations	-176	-39	-24	-31	-25	-31	-12	-12	-6.74	-16
Total Pre-Tax Income	-176	-39	-24	-31	-25	-31	-12	-13	-6.74	-16
Total Operating Income	-188	-41	-24	-32	-36	-23	-14	-12	-8.32	-12
Total Gross Profit	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.25
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.61
Total Cost of Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.35
Total Operating Expenses	188	41	24	32	36	23	14	12	8.32	12
Selling, General & Admin Expense	106	13	9.84	11	8.76	6.93	6.56	6.58	6.08	6.14
Research & Development Expense	79	25	15	21	23	16	7.18	3.07	2.25	4.54
Other Operating Expenses / (Income)	3.24	2.71	-0.71	-0.73	4.34	0.29	0.57	2.49	-	-
Total Other Income / (Expense), net	12	2.40	0.33	0.62	12	-7.29	2.46	-1.27	1.59	-3.75
Interest Expense	0.23	0.00	0.00	-	-	-	-	-	-	-
Interest & Investment Income	12	2.58	0.30	-	-	-0.48	1.83	-	-	-
Other Income / (Expense), net	0.00	-0.18	0.03	0.62	12	-6.81	0.63	-1.27	1.59	-3.75
Basic Earnings per Share	($4.38)	($2.36)	($2.87)	($5.81)	($0.39)	($0.90)	($0.64)	($1.71)	($5.07)	($1.69)
Weighted Average Basic Shares Outstanding	40.18M	16.49M	8.40M	5.32M	62.62M	34.14M	20.98M	8.98M	3.10M	9.43M
Diluted Earnings per Share	($4.38)	($2.36)	($2.87)	($5.81)	($0.39)	($0.90)	($0.64)	($1.71)	($5.07)	($1.69)
Weighted Average Diluted Shares Outstanding	40.18M	16.49M	8.40M	5.32M	62.62M	34.14M	20.98M	8.98M	3.10M	9.43M
Weighted Average Basic & Diluted Shares Outstanding	45.86M	32.46M	8.17M	79.77M	62.62M	34.14M	20.98M	8.98M	3.10M	9.43M

This table shows Soleno Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	-44	-56	-77	-22	-21	-11	-11	-8.48	-8.36	-5.49	-6.13
Consolidated Net Income / (Loss)	-44	-56	-77	-22	-21	-11	-11	-8.48	-8.36	-5.49	-6.13
Net Income / (Loss) Continuing Operations	-44	-56	-77	-22	-21	-11	-11	-8.48	-8.36	-5.49	-6.13
Total Pre-Tax Income	-44	-56	-77	-22	-21	-11	-11	-8.48	-8.36	-5.49	-6.13
Total Operating Income	-46	-59	-80	-25	-23	-14	-10	-8.62	-8.47	-5.61	-6.24
Total Gross Profit	0.00	-	0.00	0.00	0.00	-	0.00	0.00	0.00	-	0.00
Total Revenue	0.00	-	0.00	0.00	0.00	-	0.00	0.00	0.00	-	0.00
Total Cost of Revenue	0.00	-	0.00	0.00	0.00	-	0.00	0.00	0.00	-	0.00
Total Operating Expenses	46	59	80	25	23	14	10	8.62	8.47	5.61	6.24
Selling, General & Admin Expense	29	37	49	11	8.47	4.14	3.32	3.17	2.85	2.40	2.33
Research & Development Expense	14	21	30	12	15	8.69	6.04	5.14	5.32	3.81	3.77
Other Operating Expenses / (Income)	2.97	0.33	0.88	1.64	0.40	1.08	1.02	0.31	0.30	-0.60	0.13
Total Other Income / (Expense), net	1.97	3.13	3.60	3.01	2.08	2.61	-0.48	0.15	0.11	0.12	0.10
Interest Expense	1.36	-	-	-	-	-	-	-	-	-	-
Interest & Investment Income	3.33	3.37	3.60	3.01	2.08	2.14	0.17	0.15	0.11	-	-
Other Income / (Expense), net	0.00	-	0.00	0.00	-	-	-0.65	0.00	-	-0.18	0.10
Basic Earnings per Share	($0.95)	($1.39)	($1.83)	($0.57)	($0.59)	$0.28	($0.95)	($0.81)	($0.88)	($0.43)	($0.65)
Weighted Average Basic Shares Outstanding	46.18M	40.18M	41.88M	38.63M	36.21M	16.49M	11.44M	10.42M	9.45M	8.40M	9.42M
Diluted Earnings per Share	($0.95)	($1.39)	($1.83)	($0.57)	($0.59)	$0.28	($0.95)	($0.81)	($0.88)	($0.43)	($0.65)
Weighted Average Diluted Shares Outstanding	46.18M	40.18M	41.88M	38.63M	36.21M	16.49M	11.44M	10.42M	9.45M	8.40M	9.42M
Weighted Average Basic & Diluted Shares Outstanding	50.39M	45.86M	43.12M	38.87M	33.41M	32.46M	30.50M	9.99M	8.17M	8.17M	8.16M

This table details how cash moves in and out of Soleno Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Net Change in Cash & Equivalents	-82	155	-6.70	-28	28	-2.37	5.96	14	-2.50	-2.46
Net Cash From Operating Activities	-69	-25	-21	-28	-25	-17	-12	-9.95	-13	-10
Net Cash From Continuing Operating Activities	-69	-25	-21	-28	-25	-17	-10	-6.92	-7.26	-10
Net Income / (Loss) Continuing Operations	-176	-39	-24	-31	-25	-31	-12	-15	-6.74	-16
Consolidated Net Income / (Loss)	-176	-39	-24	-31	-25	-31	-13	-15	-12	-16
Depreciation Expense	1.99	1.96	1.96	1.96	1.95	1.96	1.96	1.61	0.02	0.11
Amortization Expense	-4.90	0.00	0.00	-	-	-	-	-	-	-
Non-Cash Adjustments To Reconcile Net Income	102	9.33	1.88	1.96	-8.06	11	-0.77	6.04	-0.90	4.69
Changes in Operating Assets and Liabilities, net	7.59	2.76	-0.56	-0.78	5.53	0.82	0.33	0.82	0.36	0.81
Net Cash From Investing Activities	-226	0.00	-0.01	-0.02	-0.01	0.53	-0.18	0.15	-0.04	-1.32
Net Cash From Continuing Investing Activities	-226	0.00	-0.01	-0.02	-0.01	0.53	-0.01	-0.56	-0.01	-1.32
Purchase of Property, Plant & Equipment	-0.22	0.00	-0.01	-0.02	-0.01	-0.02	-0.01	-0.58	-0.01	-0.06
Purchase of Investments	-356	0.00	0.00	-	-	-	-	-	-	-
Sale and/or Maturity of Investments	131	0.00	0.00	-	-	-	-	-	-	-
Net Cash From Financing Activities	213	180	14	-0.13	54	14	18	24	11	9.16
Net Cash From Continuing Financing Activities	213	180	14	-0.13	54	14	16	24	11	5.21
Issuance of Debt	50	0.00	0.00	-	-	-	-	-	-	0.10
Issuance of Common Equity	149	138	14	0.00	54	14	16	25	0.00	2.01
Other Financing Activities, net	14	42	-0.02	-0.13	0.00	0.00	-	-1.06	-0.05	0.37

This table details how cash moves in and out of Soleno Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	-6.60	40	-8.61	14	-127	117	33	11	-6.73	-5.15	-4.31
Net Cash From Operating Activities	-33	-24	-15	-18	-13	-6.31	-6.33	-5.57	-6.73	-5.14	-4.66
Net Cash From Continuing Operating Activities	-33	-24	-15	-18	-13	-6.31	-6.33	-5.57	-6.73	-5.14	-4.66
Net Income / (Loss) Continuing Operations	-44	-56	-77	-22	-21	-11	-11	-8.48	-8.36	-5.49	-6.13
Consolidated Net Income / (Loss)	-44	-56	-77	-22	-21	-11	-11	-8.48	-8.36	-5.49	-6.13
Depreciation Expense	0.50	0.50	0.50	0.49	0.49	0.49	0.49	0.49	0.49	0.49	0.49
Amortization Expense	-0.97	-1.40	-1.91	-1.11	-0.47	-	-	-	0.00	-	-
Non-Cash Adjustments To Reconcile Net Income	18	30	57	8.34	5.92	2.74	3.71	1.56	1.32	0.39	0.67
Changes in Operating Assets and Liabilities, net	-6.35	2.55	5.61	-3.51	2.94	1.75	0.33	0.86	-0.18	-0.54	0.32
Net Cash From Investing Activities	23	6.44	4.04	-121	-115	-	-	-	0.00	-0.01	-
Net Cash From Continuing Investing Activities	23	6.44	4.04	-121	-115	-	-	-	0.00	-0.01	-
Purchase of Property, Plant & Equipment	-0.01	-0.01	-0.19	-0.01	-0.01	-	-	-	0.00	-0.01	-
Purchase of Investments	-45	-48	-48	-146	-115	-	-	-	0.00	-	-
Sale and/or Maturity of Investments	68	54	52	-	-	-	-	-	-	-	-
Net Cash From Financing Activities	3.22	57	2.28	153	0.94	124	39	17	0.00	-	0.34
Net Cash From Continuing Financing Activities	3.22	57	2.28	153	0.94	124	39	17	0.00	-	0.34
Repayment of Debt	-0.06	-	-	-	-	-	-	-	-	-	-
Issuance of Common Equity	0.00	-5.69	5.05	-	-	81	39	-	-	-	14
Other Financing Activities, net	3.28	13	-2.78	3.16	0.94	42	0.01	-	0.00	-	-14
Cash Interest Paid	0.81	-	-	-	-	-	-	-	-	-	-

This table presents Soleno Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Total Assets	331	181	26	36	65	38	43	39	5.56	8.20
Total Current Assets	294	171	16	22	50	21	25	18	3.80	6.40
Cash & Equivalents	88	170	15	21	49	21	23	17	2.73	5.49
Short-Term Investments	204	0.00	-	-	-	-	0.98	-	-	-
Prepaid Expenses	2.45	1.68	1.05	1.12	1.02	0.41	0.53	0.34	0.25	0.17
Plant, Property, & Equipment, net	0.19	0.01	0.03	0.03	0.02	0.02	0.01	0.02	0.04	0.09
Total Noncurrent Assets	37	9.32	11	13	15	17	18	21	1.72	1.71
Long-Term Investments	27	0.00	-	-	-	-	-	-	-	-
Noncurrent Note & Lease Receivables	0.00	0.00	0.00	0.00	0.02	0.02	-	-	-	-
Intangible Assets	6.81	8.75	11	13	15	17	18	20	-	0.08
Other Noncurrent Operating Assets	2.88	0.57	0.13	0.46	0.12	0.46	-	0.13	0.13	0.72
Total Liabilities & Shareholders' Equity	331	181	26	36	65	38	43	39	5.56	8.20
Total Liabilities	86	23	16	18	19	23	13	12	2.13	4.98
Total Current Liabilities	19	12	7.31	8.01	8.62	4.96	1.88	1.73	1.71	3.19
Accounts Payable	8.88	3.15	1.78	3.25	3.49	2.00	0.93	0.63	0.41	0.70
Accrued Expenses	1.83	3.39	3.22	3.42	3.79	2.00	0.32	0.97	1.05	1.63
Current Employee Benefit Liabilities	4.78	3.14	1.68	0.73	1.01	0.28	0.27	-	-	-
Other Current Liabilities	3.26	1.83	0.64	0.61	0.34	0.69	0.35	-	-	0.87
Total Noncurrent Liabilities	67	12	8.84	9.75	11	18	11	0.31	0.42	1.78
Long-Term Debt	50	0.00	-	-	-	-	-	-	-	-
Other Noncurrent Operating Liabilities	17	12	8.84	9.75	11	18	11	0.08	0.34	1.78
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	245	158	10	18	46	15	30	27	3.44	3.22
Total Preferred & Common Equity	245	158	10	18	46	15	30	27	3.44	3.22
Preferred Stock	0.00	0.00	0.00	0.00	-	-	-	-	-	-
Total Common Equity	245	158	10	18	46	15	30	27	3.44	3.22
Common Stock	697	434	248	231	228	173	157	141	102	89
Retained Earnings	-452	-276	-237	-213	-182	-158	-127	-114	-98	-86
Accumulated Other Comprehensive Income / (Loss)	0.36	0.00	-	-	-	-	-	-	-	-

This table presents Soleno Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	3/31/2025	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023	9/30/2022
Total Assets	318	297	304	169	64	31	20	32
Total Current Assets	309	258	268	151	54	20	9.13	21
Cash & Equivalents	81	48	57	43	52	19	7.87	20
Short-Term Investments	209	208	209	107	-	-	-	-
Prepaid Expenses	19	1.42	1.38	1.60	1.22	1.13	1.25	0.82
Plant, Property, & Equipment, net	0.17	0.20	0.02	0.03	0.02	0.02	0.02	0.02
Total Noncurrent Assets	9.00	38	37	18	9.87	10	10	11
Long-Term Investments	0.00	28	28	8.82	-	-	-	-
Intangible Assets	6.32	7.29	7.78	8.26	9.24	9.72	10	11
Other Noncurrent Operating Assets	2.69	3.08	0.35	0.50	0.64	0.71	0.18	0.21
Total Liabilities & Shareholders' Equity	318	297	304	169	64	31	20	32
Total Liabilities	86	32	23	25	40	19	17	17
Total Current Liabilities	16	15	9.15	13	29	8.80	7.76	7.34
Accounts Payable	5.48	6.24	3.72	8.02	3.22	3.44	2.78	2.32
Accrued Expenses	1.82	1.76	1.86	2.40	3.24	3.47	3.53	2.83
Current Employee Benefit Liabilities	4.28	3.41	2.15	1.23	1.50	1.17	0.72	1.28
Other Current Liabilities	3.72	3.55	1.42	1.82	21	0.73	0.73	0.91
Other Current Nonoperating Liabilities	0.42	-	-	-	-	-	-	-
Total Noncurrent Liabilities	70	17	14	12	11	9.72	9.14	9.44
Long-Term Debt	50	-	-	-	-	-	-	-
Other Noncurrent Operating Liabilities	20	17	14	12	11	9.72	9.14	9.44
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	232	265	281	143	23	12	2.64	15
Total Preferred & Common Equity	232	265	281	143	23	12	2.64	15
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-
Total Common Equity	232	265	281	143	23	12	2.64	15
Common Stock	728	660	601	441	288	267	248	247
Retained Earnings	-496	-396	-320	-298	-265	-254	-246	-232
Accumulated Other Comprehensive Income / (Loss)	0.23	0.90	-0.15	-0.11	-0.00	0.00	0.02	-0.00

This table displays calculated financial ratios and metrics derived from Soleno Therapeutics' official financial filings.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-100.00%	0.00%
EBITDA Growth	-381.16%	-76.80%	22.61%	-27.60%	19.95%	-141.96%	1.01%	-76.08%	57.48%	-219.14%
EBIT Growth	-351.50%	-70.58%	21.17%	-25.45%	18.67%	-121.54%	-1.73%	-99.51%	57.65%	-74.66%
NOPAT Growth	-353.49%	-69.63%	22.62%	13.12%	-54.51%	-64.23%	-17.50%	-46.21%	31.54%	-135.67%
Net Income Growth	-351.04%	-62.00%	22.14%	-25.45%	19.94%	-130.78%	13.32%	-27.52%	24.16%	-20.18%
EPS Growth	-85.59%	17.77%	50.60%	-1,389.74%	56.67%	-40.63%	62.57%	66.27%	24.16%	83.78%
Operating Cash Flow Growth	-177.05%	-20.01%	25.17%	-10.09%	-45.17%	-48.72%	-17.42%	26.29%	-31.06%	-129.67%
Free Cash Flow Firm Growth	-469.33%	-28.86%	26.54%	19.18%	-537.10%	-250.50%	109.85%	-331.82%	3.31%	-66.23%
Invested Capital Growth	-94.73%	-186.18%	-21.16%	4.51%	36.45%	-191.32%	-67.03%	1,484.30%	39.80%	-199.82%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	100.00%	-100.00%	65.98%
EBITDA Q/Q Growth	-35.65%	-27.25%	-15.24%	0.09%	34.16%	-87.00%	26.93%	-98.81%	49.02%	-6.39%
EBIT Q/Q Growth	-31.73%	-25.64%	-13.82%	0.07%	32.33%	-77.05%	24.38%	-92.09%	49.07%	-6.64%
NOPAT Q/Q Growth	-31.73%	-25.09%	-11.97%	13.58%	-3.43%	-15.87%	10.42%	-79.78%	30.82%	-15.82%
Net Income Q/Q Growth	-34.07%	-17.51%	-12.42%	0.08%	32.33%	-93.72%	27.29%	-16.07%	1.89%	21.56%
EPS Q/Q Growth	-61.62%	23.13%	55.64%	-228.25%	17.02%	-80.00%	25.58%	2.29%	1.89%	16.34%
Operating Cash Flow Q/Q Growth	-34.38%	-4.93%	7.64%	0.01%	-7.64%	-8.36%	-9.40%	-0.43%	4.86%	-21.49%
Free Cash Flow Firm Q/Q Growth	-10.02%	-1,496.55%	12.57%	13.44%	-115.47%	67.59%	212.39%	-38.05%	45.64%	0.00%
Invested Capital Q/Q Growth	-18.40%	58.33%	6.53%	56.01%	54.78%	-258.09%	39.99%	15.62%	-629.82%	38.05%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	41.94%
EBITDA Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-2,601.00%
Operating Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-2,001.70%
EBIT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-2,618.81%
Profit (Net Income) Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-2,618.81%
Tax Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	112.62%	114.45%	179.07%	100.00%
Interest Burden Percent	93.70%	93.80%	98.77%	100.00%	100.00%	101.58%	86.59%	100.00%	100.00%	100.00%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-87.35%	-46.45%	-171.05%	-97.60%	-81.46%	-135.69%	-46.60%	-101.71%	-362.37%	399.40%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	22.46%	-151.56%	0.00%	0.00%
Operating Return on Assets (OROA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-191.70%
Return on Assets (ROA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-191.70%
Return on Common Equity (ROCE)	-87.35%	-46.45%	-171.05%	-97.60%	-81.46%	-135.69%	-46.60%	-101.71%	-362.37%	399.40%
Return on Equity Simple (ROE_SIMPLE)	-71.74%	-24.75%	-232.58%	-173.72%	-54.10%	-205.89%	-43.85%	-57.37%	-351.22%	-493.47%
Net Operating Profit after Tax (NOPAT)	-131	-29	-17	-22	-25	-16	-10	-8.52	-5.83	-8.51
NOPAT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-1,401.19%
Net Nonoperating Expense Percent (NNEP)	-20.29%	-10.87%	-38.93%	-25.07%	2.18%	-63.98%	-20.99%	-110.51%	-120.51%	302.44%
Return On Investment Capital (ROIC_SIMPLE)	-44.54%	-18.39%	-165.04%	-	-	-	-	-	-	-
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	58.06%
SG&A Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	1,010.88%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	746.74%
Operating Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	2,043.64%
Earnings before Interest and Taxes (EBIT)	-188	-42	-24	-31	-25	-30	-14	-13	-6.74	-16
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-191	-40	-22	-29	-23	-28	-12	-12	-6.72	-16
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	7.91	7.79	1.56	0.12	0.22	0.59	0.08	0.04	0.00	0.00
Price to Tangible Book Value (P/TBV)	8.13	8.25	0.00	0.42	0.33	0.00	0.20	0.19	0.00	0.00
Price to Revenue (P/Rev)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.20	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.20	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-1.09	-1.10	-1.28	-1.11	-1.16	-0.99	-0.55	-0.41	-1.55	-0.61
Leverage Ratio	1.27	1.23	2.21	1.59	1.71	1.79	1.44	1.47	2.07	-2.08
Compound Leverage Factor	1.19	1.16	2.18	1.59	1.71	1.82	1.24	1.47	2.07	-2.08
Debt to Total Capital	16.89%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	16.89%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	83.11%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	-0.26	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	1.41	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	-0.26	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	-0.38	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	2.05	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	-0.38	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	10.76	29.93	-14.60	-10.71	-4.10	-7.67	-4.42	-4.66	0.00	0.00
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	15.68	14.89	2.14	2.80	5.83	4.26	13.14	10.38	2.23	2.01
Quick Ratio	15.55	14.75	2.00	2.66	5.71	4.18	12.86	9.87	1.60	1.77
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-120	-21	-16	-22	-28	-4.32	2.87	-29	-6.74	-6.98
Operating Cash Flow to CapEx	-31,695.41%	0.00%	-159,853.85%	-126,227.27%	-360,342.86%	-82,738.10%	-146,037.50%	-1,730.43%	-91,233.39%	-18,465.19%
Free Cash Flow to Firm to Interest Expense	-518.77	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	-299.12	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	-300.06	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.07
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.07
Fixed Asset Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	8.48
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.42
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	341.70
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	870.30
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-528.59
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	-24	-12	-4.25	-3.51	-3.68	-5.79	6.34	19	-1.39	-2.31
Invested Capital Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-0.40
Increase / (Decrease) in Invested Capital	-12	-7.92	-0.74	0.17	2.11	-12	-13	21	0.92	-1.54
Enterprise Value (EV)	1,669	1,058	1.55	-19	-39	-12	-22	-16	0.00	0.00
Market Capitalization	1,938	1,228	16	2.18	10	8.75	2.44	1.20	0.00	0.00
Book Value per Share	$5.68	$5.16	$1.27	$0.22	$0.57	$0.44	$1.42	$2.68	$0.22	$0.26
Tangible Book Value per Share	$5.53	$4.88	($0.04)	$0.06	$0.39	($0.05)	$0.56	$0.64	$0.22	$0.18
Total Capital	295	158	10	18	46	15	30	27	3.44	3.22
Total Debt	50	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	50	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-269	-170	-15	-21	-49	-21	-24	-17	-2.76	-5.53
Capital Expenditures (CapEx)	0.22	0.00	0.01	0.02	0.01	0.02	0.01	0.58	0.01	0.06
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-16	-9.83	-6.27	-6.89	-7.60	-4.55	-1.28	-0.87	-0.67	-2.32
Debt-free Net Working Capital (DFNWC)	275	160	8.33	14	42	16	23	16	2.09	3.21
Net Working Capital (NWC)	275	160	8.33	14	42	16	23	16	2.09	3.21
Net Nonoperating Expense (NNE)	44	10	6.99	8.84	-0.76	14	3.32	6.87	6.24	7.40
Net Nonoperating Obligations (NNO)	-269	-170	-15	-21	-49	-21	-24	-7.60	-4.82	-5.53
Total Depreciation and Amortization (D&A)	-2.91	1.96	1.96	1.96	1.95	1.96	1.96	1.61	0.02	0.11
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-381.57%
Debt-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	528.68%
Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	528.68%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($4.38)	($2.36)	($2.87)	($5.85)	($5.85)	($13.50)	($9.60)	($26.25)	($75.75)	($126.75)
Adjusted Weighted Average Basic Shares Outstanding	40.18M	16.49M	8.40M	5.34M	5.31M	2.98M	2.12M	1.30M	633.07K	205.40K
Adjusted Diluted Earnings per Share	($4.38)	($2.36)	($2.87)	($5.85)	($5.85)	($13.50)	($9.60)	($26.25)	($75.75)	($126.75)
Adjusted Weighted Average Diluted Shares Outstanding	40.18M	16.49M	8.40M	5.34M	5.31M	2.98M	2.12M	1.30M	633.07K	205.40K
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	($5.85)	($5.85)	($13.50)	($9.60)	($26.25)	($75.75)	($126.75)
Adjusted Weighted Average Basic & Diluted Shares Outstanding	45.86M	32.46M	8.17M	5.32M	4.17M	2.28M	1.40M	598.52K	206.77K	125.68K
Normalized Net Operating Profit after Tax (NOPAT)	-131	-29	-17	-22	-25	-16	-10	-8.52	-5.83	-8.51
Normalized NOPAT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-1,401.19%
Pre Tax Income Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-2,618.81%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-812.43	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	-568.70	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	-813.37	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	-569.64	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Soleno Therapeutics' official financial filings.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Growth	-96.99%	-347.16%	-674.03%	-213.38%	-194.00%	-153.32%	-86.97%	-30.48%	-52.50%	-126.80%	26.26%
EBIT Growth	-94.86%	-324.99%	-626.89%	-188.43%	-177.19%	-140.41%	-79.96%	-28.21%	-47.96%	-104.60%	24.67%
NOPAT Growth	-94.86%	-324.99%	-672.61%	-188.39%	-177.19%	-147.95%	-66.51%	-27.20%	-46.70%	-86.94%	24.75%
Net Income Growth	-104.57%	-395.59%	-605.42%	-157.86%	-156.08%	-105.91%	-77.12%	-26.02%	-45.98%	-93.99%	24.67%
EPS Growth	-61.02%	-596.43%	-92.63%	29.63%	32.95%	165.12%	-46.15%	-12.50%	17.76%	89.33%	57.52%
Operating Cash Flow Growth	-161.43%	-279.97%	-135.72%	-217.12%	-86.21%	-22.77%	-36.00%	-20.48%	-5.75%	25.06%	13.87%
Free Cash Flow Firm Growth	-500.29%	-1,542.72%	-475.57%	-268.34%	-111.22%	42.93%	323.19%	60.11%	44.61%	-40.47%	-31.03%
Invested Capital Growth	50.67%	-94.73%	31.47%	-99.48%	-187.72%	-186.18%	-541.99%	-84.78%	-115.08%	-21.16%	42.98%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Q/Q Growth	23.00%	26.47%	-220.25%	-8.65%	-74.79%	-27.27%	-29.66%	-1.93%	-59.64%	6.06%	9.51%
EBIT Q/Q Growth	22.62%	26.30%	-222.55%	-5.93%	-68.76%	-26.05%	-27.99%	-1.81%	-54.37%	5.64%	8.82%
NOPAT Q/Q Growth	22.62%	26.30%	-222.55%	-5.93%	-68.76%	-33.98%	-20.40%	-1.82%	-50.96%	10.02%	8.02%
Net Income Q/Q Growth	21.81%	26.93%	-250.58%	-2.13%	-89.43%	-4.01%	-28.15%	-1.42%	-52.32%	10.53%	8.82%
EPS Q/Q Growth	31.65%	24.04%	-221.05%	3.39%	-310.71%	129.47%	-17.28%	7.95%	-104.65%	33.85%	9.72%
Operating Cash Flow Q/Q Growth	-36.52%	-60.73%	15.44%	-40.89%	-98.42%	0.28%	-13.76%	17.27%	-30.82%	-10.46%	-0.78%
Free Cash Flow Firm Q/Q Growth	-32.85%	54.32%	-522.22%	-58.98%	-263.54%	-110.44%	710.24%	8.83%	1.78%	59.16%	-9.07%
Invested Capital Q/Q Growth	68.66%	-18.40%	-44.58%	8.06%	-23.72%	58.33%	-320.87%	-32.61%	-23.06%	6.53%	-21.13%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBIT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Profit (Net Income) Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Tax Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Interest Burden Percent	95.69%	94.70%	95.52%	87.88%	91.15%	81.21%	98.42%	98.30%	98.67%	94.82%	100.00%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-105.54%	-87.35%	-91.11%	-44.62%	-71.26%	-46.45%	-172.71%	-173.82%	-183.50%	-171.05%	-120.94%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Assets (ROA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Common Equity (ROCE)	-105.54%	-87.35%	-91.11%	-44.62%	-71.26%	-46.45%	-172.71%	-173.82%	-183.50%	-171.05%	-120.94%
Return on Equity Simple (ROE_SIMPLE)	-85.35%	0.00%	-49.55%	-23.30%	-36.29%	0.00%	-142.89%	-228.95%	-1,011.71%	0.00%	-140.85%
Net Operating Profit after Tax (NOPAT)	-32	-41	-56	-17	-16	-9.74	-7.27	-6.04	-5.93	-3.93	-4.36
NOPAT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Nonoperating Expense Percent (NNEP)	-5.90%	-6.66%	-12.14%	-2.83%	-5.97%	-1.69%	-9.96%	-11.23%	-13.21%	-8.68%	-7.37%
Return On Investment Capital (ROIC_SIMPLE)	-11.35%	-14.03%	-	-	-	-6.18%	-	-	-	-37.95%	-
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings before Interest and Taxes (EBIT)	-46	-59	-80	-25	-23	-14	-11	-8.62	-8.47	-5.79	-6.13
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-46	-60	-82	-25	-23	-13	-11	-8.13	-7.98	-5.30	-5.64
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	14.11	7.91	7.41	4.86	9.69	7.79	12.70	2.82	6.62	1.56	0.89
Price to Tangible Book Value (P/TBV)	14.50	8.13	7.62	4.99	10.28	8.25	21.08	12.96	0.00	0.00	3.36
Price to Revenue (P/Rev)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	160.85	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.21	0.20	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.21	0.20	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-1.06	-1.09	-1.17	-1.07	-1.14	-1.10	-1.88	-1.33	-1.26	-1.28	-1.35
Leverage Ratio	1.30	1.27	1.25	1.14	1.29	1.23	2.49	2.07	2.13	2.21	2.11
Compound Leverage Factor	1.24	1.20	1.20	1.00	1.18	1.00	2.45	2.04	2.10	2.09	2.11
Debt to Total Capital	17.67%	16.89%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	17.67%	16.89%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	82.33%	83.11%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	-0.23	-0.26	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	1.13	1.41	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	-0.23	-0.26	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	-0.34	-0.38	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	1.63	2.05	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	-0.34	-0.38	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	21.35	12.04	35.01	34.27	30.80	30.44	-1.56	-10.83	-18.34	-12.29	-9.81
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	19.64	15.68	17.26	29.24	11.23	14.89	1.85	2.33	1.18	2.14	2.80
Quick Ratio	18.43	15.55	17.16	29.08	11.11	14.75	1.81	2.20	1.01	2.00	2.69
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-40	-30	-65	-11	-6.61	-1.82	17	-2.85	-3.13	-3.18	-7.80
Operating Cash Flow to CapEx	-655,040.00%	-299,887.50%	-7,814.66%	-220,637.50%	-113,890.91%	0.00%	0.00%	0.00%	0.00%	-85,716.67%	0.00%
Free Cash Flow to Firm to Interest Expense	-29.13	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	-24.06	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	-24.07	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	-7.43	-24	-20	-14	-15	-12	-29	-6.94	-5.24	-4.25	-4.55
Invested Capital Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Increase / (Decrease) in Invested Capital	7.63	-12	9.20	-6.91	-9.83	-7.92	-25	-3.19	-2.80	-0.74	3.43
Enterprise Value (EV)	3,036	1,669	1,678	1,069	1,231	1,058	242	16	9.61	1.55	-6.22
Market Capitalization	3,277	1,938	1,963	1,363	1,389	1,228	295	35	17	16	14
Book Value per Share	$5.06	$5.68	$6.81	$8.40	$4.42	$5.16	$2.32	$1.52	$0.32	$1.27	$0.13
Tangible Book Value per Share	$4.93	$5.53	$6.62	$8.17	$4.16	$4.88	$1.40	$0.33	($0.93)	($0.04)	$0.03
Total Capital	282	295	265	281	143	158	23	12	2.64	10	15
Total Debt	50	50	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	50	50	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-240	-269	-285	-295	-158	-170	-52	-19	-7.87	-15	-20
Capital Expenditures (CapEx)	0.01	0.01	0.19	0.01	0.01	0.00	0.00	0.00	0.00	0.01	0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)	3.23	-16	-14	-7.77	-12	-9.83	-28	-7.67	-6.51	-6.27	-6.52
Debt-free Net Working Capital (DFNWC)	293	275	243	258	138	160	25	12	1.37	8.33	13
Net Working Capital (NWC)	293	275	243	258	138	160	25	12	1.37	8.33	13
Net Nonoperating Expense (NNE)	12	15	20	4.45	4.97	1.56	3.59	2.44	2.43	1.56	1.77
Net Nonoperating Obligations (NNO)	-240	-269	-285	-295	-158	-170	-52	-19	-7.87	-15	-20
Total Depreciation and Amortization (D&A)	-0.47	-0.90	-1.41	-0.62	0.02	0.49	0.49	0.49	0.49	0.49	0.49
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Debt-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.95)	($1.39)	($1.83)	($0.57)	($0.59)	$0.28	($0.95)	($0.81)	($0.88)	($0.43)	($0.76)
Adjusted Weighted Average Basic Shares Outstanding	46.18M	40.18M	41.88M	38.63M	36.21M	16.49M	11.44M	10.42M	9.45M	8.40M	8.09M
Adjusted Diluted Earnings per Share	($0.95)	($1.39)	($1.83)	($0.57)	($0.59)	$0.28	($0.95)	($0.81)	($0.88)	($0.43)	($0.76)
Adjusted Weighted Average Diluted Shares Outstanding	46.18M	40.18M	41.88M	38.63M	36.21M	16.49M	11.44M	10.42M	9.45M	8.40M	8.09M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	50.39M	45.86M	43.12M	38.87M	33.41M	32.46M	30.50M	9.99M	8.17M	8.17M	8.16M
Normalized Net Operating Profit after Tax (NOPAT)	-32	-41	-56	-17	-16	-9.74	-7.27	-6.04	-5.93	-3.93	-4.36
Normalized NOPAT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Pre Tax Income Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-33.61	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	-23.53	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	-33.61	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	-23.53	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Soleno Therapeutics' Financials

When does Soleno Therapeutics's fiscal year end?

According to the most recent income statement we have on file, Soleno Therapeutics' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Soleno Therapeutics' net income changed over the last 9 years?

Soleno Therapeutics' net income appears to be on an upward trend, with a most recent value of -$175.85 million in 2024, rising from -$15.91 million in 2015. The previous period was -$38.99 million in 2023. Check out Soleno Therapeutics' forecast to explore projected trends and price targets.

What is Soleno Therapeutics's operating income?

Soleno Therapeutics's total operating income in 2024 was -$187.67 million, based on the following breakdown:

Total Gross Profit: $0.00
Total Operating Expenses: $187.67 million

How has Soleno Therapeutics revenue changed over the last 9 years?

Over the last 9 years, Soleno Therapeutics' total revenue changed from $607.47 thousand in 2015 to $0.00 in 2024, a change of -100.0%.

How much debt does Soleno Therapeutics have?

Soleno Therapeutics' total liabilities were at $85.86 million at the end of 2024, a 270.3% increase from 2023, and a 1,625.0% increase since 2015.

How much cash does Soleno Therapeutics have?

In the past 9 years, Soleno Therapeutics' cash and equivalents has ranged from $2.73 million in 2016 to $169.68 million in 2023, and is currently $87.93 million as of their latest financial filing in 2024.

How has Soleno Therapeutics' book value per share changed over the last 9 years?

Over the last 9 years, Soleno Therapeutics' book value per share changed from 0.26 in 2015 to 5.68 in 2024, a change of 2,080.6%.

Related Companies

This page (NASDAQ:SLNO) was last updated on 5/21/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Soleno Therapeutics (SLNO) Financials

Frequently Asked Questions About Soleno Therapeutics' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Soleno Therapeutics (SLNO) Financials

Annual Income Statements for Soleno Therapeutics

Quarterly Income Statements for Soleno Therapeutics

Annual Cash Flow Statements for Soleno Therapeutics

Quarterly Cash Flow Statements for Soleno Therapeutics

Annual Balance Sheets for Soleno Therapeutics

Quarterly Balance Sheets for Soleno Therapeutics

Annual Metrics And Ratios for Soleno Therapeutics

Quarterly Metrics And Ratios for Soleno Therapeutics

Frequently Asked Questions About Soleno Therapeutics' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools